Vivani Medical, Inc. (VANI)
NASDAQ: VANI · Real-Time Price · USD
1.225
-0.005 (-0.41%)
Sep 16, 2026, 2:38 PM EDT - Market open
Vivani Medical Employees
Vivani Medical had 42 employees as of December 31, 2025. The number of employees increased by 5 or 13.51% compared to the previous year.
Employees
42
Change (1Y)
5
Growth (1Y)
13.51%
Revenue / Employee
n/a
Profits / Employee
-$626,500
Market Cap
110.50M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 42 | 5 | 13.51% |
| Dec 31, 2024 | 37 | -7 | -15.91% |
| Dec 31, 2023 | 44 | -6 | -12.00% |
| Dec 31, 2022 | 50 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Nautilus Biotechnology | 127 |
| Seer, Inc. | 124 |
| Rani Therapeutics Holdings | 71 |
| Aardvark Therapeutics | 28 |
| Genelux | 26 |
| Black Diamond Therapeutics | 21 |
| Tenax Therapeutics | 16 |
VANI News
- 5 days ago - Vivani Medical Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 12 days ago - Vivani Medical Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Vivani Medical Slides: Investor presentation - Filings
- 4 weeks ago - Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Vivani Medical Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Vivani Medical Earnings release: Q2 2026 - Filings
- 5 weeks ago - Vivani Medical announces full enrollment, initial dosing in SLIM-1 trial - TheFly
- 5 weeks ago - Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - GlobeNewsWire